ClinicalTrials.Veeva

Menu

Observational Study in Patients With HIV Infection Type 1 After Switching to a Viramune®-Containing Therapy Regimen

Boehringer Ingelheim logo

Boehringer Ingelheim

Status

Completed

Conditions

HIV Infections

Treatments

Drug: Viramune

Study type

Observational

Funder types

Industry

Identifiers

NCT02191332
1100.1305

Details and patient eligibility

About

Observational study to collect data on maintaining anti-retroviral activity (quantitative HIV RNA determination) and immunological activity (CD4 cells) despite switching from protease inhibitor to nonnucleoside reverse transcriptase inhibitor (NNRTI) (Viramune®).

Enrollment

147 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult male or female patients with HIV type 1 infection

Exclusion criteria

  • Counter-indications according to summary of product characteristics (SPC) for Viramune tablets
  • No persons under 18
  • Pregnancy and breast-feeding
  • Use of oral contraceptives
  • Use of drugs affecting CYP450 3A metabolism

Trial design

147 participants in 1 patient group

Viramune
Treatment:
Drug: Viramune

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems